Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

October 2024

Efficacy and safety of intravenous secukinumab for the treatment of active psoriatic arthritis: Results from the randomized, placebo-controlled Phase III INVIGORATE-2 study

Arthritis Rheumatol 2024 doi: 10.1002/art.42997

Kotha R,

Zhu X,

IV secukinumab provided rapid and sustained improvements in disease signs and symptoms at Week 16 and through 52 weeks. Kivitz et al. evaluated the long-term efficacy, safety, and tolerability of IV secukinumab in patients with active PsA.

Keywords:

September 2024

A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis

Br J Dermatol. 2024 Aug 14;191:336-343 doi:10.1093/bjd/ljae062

Cai L,

Jiang C,

Zhang G,

Fang H,

Wang J,

Li Y,

Xu H,

Xiao R,

Ding Y,

Huang K,

Zhang C,

Zhang L,

Chen B,

Duan X,

Pan W,

Han G,

Chen R,

Liu L,

Zhang S,

Tao J,

Pang X,

Yu J,

Wang H,

Zhao Y,

Li C,

Kang X,

Qin L,

Zhu X,

Su J,

Li S,

Yang C,

Feng W,

Lei T,

Jiang S,

Fang R,

Lin M,

Lu Q,

Xu C,

Wang W,

Zhang J

Cai et al. demonstrated that xeligekimab significantly improved the Psoriasis Area and Severity Index (PASI) scores in patients with moderate-to-severe plaque psoriasis, with 90.7% achieving PASI 75 at week 12. Xeligekimab was well-tolerated with no unexpected safety concerns.